AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?

Lignende værker

• Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
  af: White, Maya N, et al.
  Udgivet: (2021)
• Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC—opportunities and obstacles
  af: Parris, Brielle A., et al.
  Udgivet: (2021)
• Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?
  af: Hirsch, Fred R.
  Udgivet: (2014)
• First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
  af: Ricciuti, Biagio, et al.
  Udgivet: (2018)
• Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
  af: Wen, Miaomiao, et al.
  Udgivet: (2018)